GI

EndoSound® Receives 510(k) Clearance for Breakthrough EVS® Innovation, a novel Endoscopic Ultrasound (EUS) technology

Retrieved on: 
Tuesday, January 2, 2024
Medical Devices, FDA, Health, Health Technology, Clinical Trials, General Health, Liver, Inc., Ecosystem, Gallbladder, ASC, Patient safety, Pancreas, Tissue, Therapy, GI, EVS, Infection, EUS, Patient, Safety, Medical device

The EVS is a novel endoscopic ultrasound (EUS) device that attaches to upper gastrointestinal endoscopes.

Key Points: 
  • The EVS is a novel endoscopic ultrasound (EUS) device that attaches to upper gastrointestinal endoscopes.
  • "We are thrilled to receive 510(k) clearance for our EVS, a testament to the dedication and innovation of the entire EndoSound team.
  • Endoscopic Ultrasound (EUS) is a minimally invasive procedure performed to assess diseases of the GI tract and other nearby organs and tissues.
  • EndoSound is dedicated to expanding access to endoscopic ultrasound technology around the world.

EndoQuest™ Robotics Accepted for Inclusion in FDA's Safer Technologies Program (STeP)

Retrieved on: 
Tuesday, January 2, 2024
Food, Physician, Step, FDA, GI, Patient, Safety, Robotics, Medical device

HOUSTON, Jan. 2, 2024 /PRNewswire/ -- EndoQuest Robotics, Inc., (the "Company") a privately-held medical device company and pioneering leader in the development of innovative endoluminal robotic technologies, announced today that the Company's Flexible Robotic System has been accepted into the U.S. Food and Drug Administration's Safer Technologies Program (STeP).

Key Points: 
  • HOUSTON, Jan. 2, 2024 /PRNewswire/ -- EndoQuest Robotics, Inc., (the "Company") a privately-held medical device company and pioneering leader in the development of innovative endoluminal robotic technologies, announced today that the Company's Flexible Robotic System has been accepted into the U.S. Food and Drug Administration's Safer Technologies Program (STeP).
  • The FDA's Safer Technologies Program is designed for devices expected to substantially enhance the safety of existing treatment options.
  • The FDA describes the Safer Technologies Program as "a collaborative program intended to help reduce the time it takes to develop and obtain marketing authorization for eligible devices.
  • "We are tremendously gratified by FDA's decision to include our Flexible Robotic System in the Safer Technologies Program," said Kurt Azarbarzin, CEO of EndoQuest Robotics.

The Most Anticipated News At The End Of 2023 For Laser Engraving Enthusiastic

Retrieved on: 
Friday, December 29, 2023
Sale, News, Water chiller, GI, Temperature, Smoke, Goggles, Final, Longevity, CO2, Dust, Telescopic sight

CHICAGO, Dec. 28, 2023 /PRNewswire/ -- One of the highlights of the anticipated news at the end of 2023 for laser engraving enthusiasts is the Holiday Final Event hosted by Monport Laser .

Key Points: 
  • CHICAGO, Dec. 28, 2023 /PRNewswire/ -- One of the highlights of the anticipated news at the end of 2023 for laser engraving enthusiasts is the Holiday Final Event hosted by Monport Laser .
  • After hard work and development over the past year, Monport Laser has emerged as a prominent supplier of top-notch laser engraving machines .
  • CO2 laser rotary attachments provide similar functionality as fiber laser rotary attachments but are specifically tailored to CO2 laser engraving machines.
  • Join the Final Holiday Event and experience the satisfaction of creating top-notch engravings with Monport's cutting-edge laser engraving accessories.

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Retrieved on: 
Tuesday, December 19, 2023
Janus, Disease, Tyrosine kinase inhibitor, Dicarboxylic acid, Antibody, Inflammatory bowel disease, B cell, Gastrointestinal disease, Patent, Integrin, Gastrointestinal tract, SAN, Therapy, JAK, GI, IP, Device, Janus kinase, Peptide, United States patent law, Chemokine, Ulcerative colitis, Pharmaceutical industry

SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development.
  • 17/313,339, entitled “Treatment of a Disease of the Gastrointestinal Tract with a JAK Inhibitor and Devices,” will issue as US Patent No.
  • The patent covers many JAK inhibitors, including those that are approved or in development for a range of indications.

Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population

Retrieved on: 
Monday, December 18, 2023
Stomach, Food, Division, Physician, FDA, Helicobacter pylori, Disease, Laboratory, GI, Patient, Food and Drug Administration, Vaccine

H. pylori infection is a disease which affects half the population of the world.

Key Points: 
  • H. pylori infection is a disease which affects half the population of the world.
  • The Biomerica Hp Detect™ test detects the presence of the H. pylori bacteria which infects approximately 35% of the U.S. population.
  • Physicians and medical centers will be able use the results from the Hp Detect™ Stool Antigen test to diagnose the presence of H. pylori and assess H. pylori infection status after treatment.
  • We have also created an efficient, low-cost manufacturing process that should enable high gross margins on this product.”

Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride

Retrieved on: 
Thursday, November 30, 2023
FACC, Pharmacokinetics, Patent, Gastroparesis, GI, Gastroesophageal reflux disease, Patient, Safety, Pharmaceutical industry

11,643,409) and a method of use patent (Patent no.

Key Points: 
  • 11,643,409) and a method of use patent (Patent no.
  • 11,827,631), both covering a novel crystal isoform of naronapride.
  • The new patents are currently being prosecuted worldwide including EP, Japan, and Greater China.
  • Renexxion is currently prosecuting these patents in EP, Japan, and greater China.

Aurora Cloud Console Goes Live: Streamlining Blockchain Business Management for Companies

Retrieved on: 
Wednesday, November 29, 2023
Cloud, Maker, Google Cloud, Ecosystem, Sale, KYC, Software as a service, ENP, Health, Logic, GI, PC Club, Web3, AMM, Cryptocurrency

Gibraltar, GI, Nov. 29, 2023 (GLOBE NEWSWIRE) --  Aurora Labs introduces Aurora Cloud and the Aurora Cloud Console, a market-first platform uniquely designed to streamline business management and set new benchmarks for seamless blockchain integration.

Key Points: 
  • Gibraltar, GI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Aurora Labs introduces Aurora Cloud and the Aurora Cloud Console, a market-first platform uniquely designed to streamline business management and set new benchmarks for seamless blockchain integration.
  • The Aurora Cloud Console is the cornerstone of this initiative.
  • The Aurora Cloud Console is now live, with a user-centric interface for effortless management of your business.
  • The roadmap for Aurora Cloud envisions a future where the console evolves into a fully autonomous system, lowering the technical barriers to blockchain utilization.

Global Disposable Endoscope Market Analysis & Forecast to 2028 - Rising Preference of Single Use Endoscopes over Traditional Endoscopes - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
General Health, Health, Medical Devices, Endoscopy, FDA, Incidence, Hospital, GI, Cancer, Fungal infection, Growth, HAI, Investment, Diagnosis, Organization, Medical device

In 2022, the global disposable endoscope market was valued at US$1.58 billion, and is probable to reach US$4.11 billion by 2028.

Key Points: 
  • In 2022, the global disposable endoscope market was valued at US$1.58 billion, and is probable to reach US$4.11 billion by 2028.
  • The growing incidences of hospital-acquired infections (HAI) due to the usage of infected endoscopes is expected to be the key factor driving the global disposable endoscope market during the forecast period.
  • The global disposable endoscope market value is projected to grow at a CAGR of 17.31%, during the forecast period of 2023-2028.
  • Furthermore, availability of robust product portfolio of technologically advanced ureteroscopes has created a lucrative growth potential for disposable endoscope market.

SNICKERS® Launched Brand New Bar Featuring Low GI Dark Chocolate Cereal in Mono Material Flexible Packaging

Retrieved on: 
Tuesday, December 26, 2023
Dietary fiber, Food, Classification, Recycling, PP, Collection, Seed, Food safety, Nutritional science, Dow, Food industry, Glycemic index, Forest Stewardship Council, Inulin, GI, P&G, Humidity, H&W, Hazelnut, PepsiCo, FSC

Typically, flexible packaging consists of multiple layers of different materials, meeting food safety requirements while being lightweight and flexible.

Key Points: 
  • Typically, flexible packaging consists of multiple layers of different materials, meeting food safety requirements while being lightweight and flexible.
  • The SNICKERS® dark chocolate cereal bar features individual packaging made from recyclable mono-polypropylene material, aligning with the principle of "Designed For Recycling", and meeting relevant Chinese standards.
  • The mono-material flexible packaging of the new SNICKERS® dark chocolate cereal bar is specifically designed by the recycling requirements of the " Flexible Plastics Reborn" project.
  • Beyond featuring sustainable packaging, the new SNICKERS® low GI dark chocolate cereal bar is a lightweight and delicious snack.

NeurAxis Secures $3 Million Financing

Retrieved on: 
Tuesday, November 14, 2023
Marketing, Neuraxis, GI, NYSE, FDA, Policy, Security (finance), RED

CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has secured a $3 million financing for NeurAxis through a preferred stock offering priced at $2.38 per share.

Key Points: 
  • CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has secured a $3 million financing for NeurAxis through a preferred stock offering priced at $2.38 per share.
  • The transaction by affiliates of Inspire Health Alliance, who have a strong presence in the GI and pediatric space, is to help fund additional sales and marketing resources as the company continues to ramp up commercialization efforts.
  • “We are focused on driving market penetration of our therapies, led by our proprietary IB-Stim™ technology and beginning 2024, our innovative rectal expulsion device (RED).
  • This committed funding adds to our growth capital to further support and accelerate NeurAxis’ sales and marketing efforts,” said Brian Carrico, President and Chief Executive Officer of NeurAxis.